Accordingly, the most favorable clinical response has been observed in patients who retain NK cell markers in the tumor infiltrate (26) and display peripheral NK cells with higher cytotoxic potential (6, 7), dependent on CD16 expression (6, 85). This evidence concerns the gene FCGR3A and neoplasm.